• Gabapentinoids were associated with increased risk of stroke after five years of use
• Heart failure was not increased with the use of gabapentinoids.
• Their chronic use was associated with increased risk of PVD after one year [HR 1.41(1.18, 1.67); P=0.0001] and five years [HR 1.58 (1.16, 2.15); I2=83%; P=0.003] use.
• Gabapentinoid use was associated with increased risk of DVT after three months [HR 1.37(1.21, 1.55); P<0.00001], one-year [HR 1.42 (1.15, 1.74); P=0.0009], and five years [HR 1.78 (1.31,2.40); I2=71%; P=0.0002] use.
• Their use was associated with increased risk of pulmonary embolism after three months [HR 1.27 (1.09, 1.46); P=0.002], one-year [HR 1.23 (1.01, 1.40); P=0.04], and five years of [HR 1.86 (1.64, 2.09); I2=0%; P<0.0001] use.
• Interpretation & conclusions: The use of gabapentinoids was associated with increased risks of thrombotic events as early as three months of use, and with increased risk of cardiovascular events on prolonged use of more than a year duration.

Quellen: Dutta D, Mohindra R, Kumar M, Banerjee M, Sharma M, Mukhopadhyay S. Cardiovascular safety of gabapentinoids gabapentin & pregabalin: A systematic review. Indian J Med Res. 2025 Apr;161(4):363-374. doi: 10.25259/IJMR_1990_2024. PMID: 40536375; PMCID: PMC12178190.